Dr Frédéric Triebel | Chief Scientific Officer and Medical Officer
Prima Biomed, Ltd

Dr Frédéric Triebel, Chief Scientific Officer and Medical Officer, Prima Biomed, Ltd

Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001). Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he
discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while being also involved in the biological
follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996.
First trained as a clinical haematologist, Dr. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics, leading to 145 publications and 18 patents.
Immutep is now part of Prima Biomed Ltd and Dr. Triebel serves as the CSO/CMO of the company.


WIC 2017 Day 1, Tuesday 31st October 2017 @ 17:50

TACTI-mel, two ACTive immunotherapies in melanoma: combination of an APC activator (IMP321 or LAG-3Ig) with Pembrolizumab

  • Enhance immune response by targeting LAG-3
  • Understand the rationale for combining an Antigen Presenting Cell (APC) activator, LAG-3Ig, with an Immune Checkpoint Inhibitor (ICI), pembrolizumab: in vitro and in vivo preclinical data
  • Evaluation of the combination in metastatic melanoma (TACTI-mel phase I trial)

back to speakers